@FiercePharma: Onyx investors sue over $10.4B Amgen buyout, saying too favorable to Amgen. More from Bloomberg | Follow @FiercePharma
@EricPFierce: FDA approval of Abraxane for pancreatic cancer should extend lives for patients and sales for Celgene. ICYMI Friday | Follow @EricPFierce
@CarlyHFierce: The DoJ probes GSK for U.S. bribery violations in China, Reuters reports. FCPA probe of entire industry. Story | Follow @CarlyHFierce
> Johnson & Johnson ($JNJ) recalled 200,000 bottles of Motrin Infants Drops because they might have been contaminated with tiny particles of plastic. Report
> Onyx Pharmaceuticals ($ONXX) investors sued the company, claiming its planned $10.4 billion sale to Amgen ($AMGN) favors the buyer and that conflicts of interest "infected" the deal. Report
> Sagent Pharmaceuticals ($SGNT) announced a 4.44 million-share offering, comprising 3.38 million shares offered by the company and 1.06 million offered by selling shareholders. Report
> Former GlaxoSmithKline ($GSK) chairman Sir Richard Sykes now chairs a company, NetScientific, that plans to go public in the U.K. later this month. Report
> The Association of the British Pharmaceutical Industry's watchdog panel said Gedeon Richter breached its promotional code of practice. Report
@FierceMedDev: From FierceDiagnostics: T2 jumps into pivotal trial for Candida assay. Article | Follow @FierceMedDev
@DamianFierce: After 22 years at the helm, AMRI's CEO is stepping down at year's end. Story from FierceCRO | Follow @DamianFierce
@MarkHFierce: J&J is sizing up buyers for its Ortho Clinical Diagnostics unit. Will it go for $5B? More | Follow @MarkHFierce
@MichaelGFierce: ICYMI: Capsugel picks up Bend Research with dispersion delivery tech. Story from FierceDrugDelivery | Follow @MichaelGFierce
> Baxter finally closes $4B Gambro deal, eyes dialysis dominance. More
> CeQur's insulin pump draws $27M Series B. Article
> Sapheon nails down $19.8M for varicose vein treatment. Report
Biotech News
@FierceBiotech: New Industry Voices: Place your bets--A horse race emerges in the migraine space by Randall Schatzman, CEO of Alder. Article | Follow @FierceBiotech
@JohnCFierce: Another round of biotech IPOs is drawing near. ICYMI Friday | Follow @JohnCFierce
@Ry_McBride: GSK has given itself a dose (or doses) of online collaboration for its sales organization. More from InformationWeek | Follow @Ry_McBride
@EmilyMFierce: Potential Parkinson's-fighting compounds identified. FierceBiotech Research article | Follow @EmilyMFierce
> DRI Capital gains $1.45B in fresh firepower for drug royalty deals. Report
> Biogen fronts $100M to add Isis R&D pact on neurological diseases. Story
> Crowded field of PhIII COPD contenders will compete for blockbuster market. Article
CRO News
> Novella shuffles execs as Quintiles deal pends. Item
> AMRI chief stepping down at year's end. News
> Patheon posts Banner quarter on 30% sales surge. Article
> Covance teams with Indiana U. for early trials. Story
> Capsugel snaps up Bend with eye on oral formulations. More
Biotech IT News
> GlaxoSmithKline picks up online collaboration tools for medical staffers. Report
> Texas biotech software outfit trumpets open source tools. Item
> Genentech backs development of video game for kids with cancer. More
> In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Story
> Accelrys scoops up Bay Area software firm for $15.3M. Article
And Finally... A combination of two common antiviral drugs could be useful against the respiratory virus emerging in the Middle East. Report